Highlights of SGEN's investor presentation - 3/4/2013
Here are just a few highlights of today’s presentation by SGEN CEO Clay Siegall during the Cowen & Company 33rd Annual Health Care Conference in Boston (my Internet access cut out and I missed the middle third of the session):
- Another hint that we don’t have to worry about dilution. Siegall: “Seattle Genetics is in a very good financial position that can fund our future development very strongly.”
- SGEN now has 1,200 accounts for Adcetris. Since approval, no patient has been denied coverage by any insurance company for on-label use of Adcetris.
- Several trials and partnerships are producing actual or anticipated "exciting" results. (In the past, his use of the word "exciting" has foreshadowed good things).
- Make of this what you will, but he made many mentions of Takeda. One of them: “They’ve been a great partner so far, with much more to come.”
That's all I have. I don't think he broke any new ground, but - again - I missed a chunk of this presentation.
You can listen to the replay through a link on the SGEN investor page.